PMID- 37081619
OWN - NLM
STAT- MEDLINE
DCOM- 20230719
LR  - 20230719
IS  - 1349-3329 (Electronic)
IS  - 0040-8727 (Linking)
VI  - 260
IP  - 3
DP  - 2023 Jul 15
TI  - Predictive Values of Blood Type I and Type II Interferon Production for Disease 
      Activity and Clinical Response to TNF-alpha Blocking Therapy in Patients with 
      Ankylosing Spondylitis.
PG  - 263-271
LID - 10.1620/tjem.2023.J033 [doi]
AB  - Tumor necrosis factor-alpha (TNF-alpha) blocking therapy is recommended to treat 
      ankylosing spondylitis for patients who fail to respond to nonsteroidal 
      anti-inflammatory drugs (NSAIDs). Herein, we attempt to dissect whether blood 
      type I and II interferon (IFN) production can be predictive of ankylosing 
      spondylitis progression and treatment response to the tumor necrosis factor 
      inhibitor (TNFi). A total of 50 ankylosing spondylitis patients receiving 
      originator TNFi with a 6-month period were retrospectively analyzed. The patients 
      who reached the Assessment of SpondyloArthritis international Society 40 (ASAS40) 
      response at the 6-month interval were classified as responders (n = 29) to TNFi 
      treatment, otherwise as non-responders (n = 21). The serum type I IFN activity, 
      and the serum levels of IFN-alpha and IFN-gamma in the patients at baseline were notably 
      greater than the healthy controls. Pearson correlation analysis showed positive 
      correlations in the patients between the serum type I IFN activity or the serum 
      levels of IFN-alpha and IFN-gamma, and BASDAI scores, ASDAS(CRP) or pro-inflammatory 
      factor production. The responders were demonstrated with reduced serum type I IFN 
      activity concomitant with lower serum levels of IFN-alpha and IFN-gamma compared to the 
      non-responders after anti-TNF treatment. The serum type I IFN activity, and the 
      serum levels of IFN-alpha and IFN-gamma used as a test to predict responders and 
      non-responders to anti-TNF treatment produced an area under the curve (AUC) of 
      0.837, 0.814, and 0.787, respectively. In conclusion, the study demonstrates that 
      blood type I and II IFN production may be correlated with disease activity, 
      inflammatory cytokine production, and indicative of unsatisfying response to TNFi 
      treatment in ankylosing spondylitis patients.
FAU - Hu, Yulan
AU  - Hu Y
AD  - Department of Endocrinology, the First People's Hospital of Linping District.
FAU - Lou, Bo
AU  - Lou B
AD  - Department of Endocrinology, the First People's Hospital of Linping District.
FAU - Jiang, Zhonghua
AU  - Jiang Z
AD  - Department of Endocrinology, the First People's Hospital of Linping District.
FAU - Yu, Chunchu
AU  - Yu C
AD  - Obstetrical Department, the First People's Hospital of Linping District.
LA  - eng
PT  - Journal Article
DEP - 20230420
PL  - Japan
TA  - Tohoku J Exp Med
JT  - The Tohoku journal of experimental medicine
JID - 0417355
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 82115-62-6 (Interferon-gamma)
RN  - 0 (Tumor Necrosis Factor Inhibitors)
RN  - 0 (Antirheumatic Agents)
SB  - IM
MH  - Humans
MH  - *Spondylitis, Ankylosing/drug therapy
MH  - Tumor Necrosis Factor-alpha
MH  - Interferon-gamma
MH  - Retrospective Studies
MH  - Tumor Necrosis Factor Inhibitors/therapeutic use
MH  - *Antirheumatic Agents/therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - ankylosing spondylitis
OT  - interferon-gamma
OT  - tumor necrosis factor inhibitor
OT  - type I interferon
OT  - type II interferon
EDAT- 2023/04/21 06:41
MHDA- 2023/07/19 06:43
CRDT- 2023/04/21 00:03
PHST- 2023/07/19 06:43 [medline]
PHST- 2023/04/21 06:41 [pubmed]
PHST- 2023/04/21 00:03 [entrez]
AID - 10.1620/tjem.2023.J033 [doi]
PST - ppublish
SO  - Tohoku J Exp Med. 2023 Jul 15;260(3):263-271. doi: 10.1620/tjem.2023.J033. Epub 
      2023 Apr 20.